Progonadoliberin-1

Also known as: Progonadoliberin I, GNRH1, P01148

Progonadoliberin-1, also known as gonadotropin-releasing hormone 1 (GNRH1), is a decapeptide encoded by the *GNRH1* gene (UniProt P01148). Its primary mechanism of action involves binding to the gonadotropin-releasing hormone receptor (GnRHR) on the anterior pituitary, thereby stimulating the synthesis and pulsatile secretion of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This pulsatile release is critical for normal reproductive function, as it regulates gonadal steroidogenesis and gametogenesis in both males and females. Key research findings confirm that Progonadoliberin-1 is the central hypothalamic regulator of the hypothalamic-pituitary-gonadal (HPG) axis. Approved for clinical use, synthetic analogs of this peptide (e.g., leuprolide, goserelin) are employed to either stimulate or suppress gonadotropin release, depending on the dosing regimen. Pulsatile administration is used to induce ovulation in hypogonadal infertility, while continuous administration leads to receptor desensitization and is utilized in treating hormone-sensitive cancers (e.g., prostate cancer) and conditions such as endometriosis and precocious puberty. Clinical relevance is well-established, with approved indications for assisted reproductive technology and hormone-dependent disorders. The peptide's therapeutic utility hinges on its ability to modulate the HPG axis, with extensive safety and efficacy data supporting its use. For research purposes only — not medical advice.

Key data

Mechanism of action

Stimulates the secretion of gonadotropins; it stimulates the secretion of both luteinizing and follicle-stimulating hormones

Research & studies

Frequently asked questions

Related peptides